Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | B3GNT2 | Q9NY97 | 3/20 | 0.40 |
| ▸ | DAO | P14920 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802039 | 0.84 | B3GNT2 (0.52) | KDM4EALDH1A1B3GNT2DAO | |
| SCHEMBL9368648 | 0.78 | DAO (0.44) | ALDH1A1DAO | |
| SCHEMBL9364597 | 0.74 | DAO (0.70) | KDM4EALDH1A1DAOMAPT | |
| SCHEMBL8145145 | 0.74 | DAO (0.70) | KDM4EDAO | |
| SCHEMBL9364598 | 0.74 | DAO (0.70) | DAO | |
| SCHEMBL9364786 | 0.72 | KDM4E (0.51) | POLBKDM4EALDH1A1DAOMAPT | |
| SCHEMBL9365531 | 0.71 | FASN (0.44) | DAO | |
| SCHEMBL9365381 | 0.71 | ALDH1A1 (0.48) | POLBKDM4EALDH1A1DAOMAPT | |
| SCHEMBL9368705 | 0.71 | DAO (0.48) | ALDH1A1DAOMAPT | |
| SCHEMBL9080167 | 0.71 | CA12 (0.52) | HDAC6KDM4EALDH1A1DAOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005361-B1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY | NOVO NORDISK HEALTHCARE AG (CH) | 2010-01-06 | — | — | EP | claimed |
| EP-1005361-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 2000-06-07 | — | — | EP | claimed |
| WO-1999003498-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 1999-01-28 | — | — | WO | claimed |
| US-5859010-A | ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 1999-01-12 | — | — | US | claimed |
| WO-1997049684-A1 | FACTOR VII-BINDING REAGENT | NOVO NORDISK A/S (DK) | 1997-12-31 | — | — | WO | claimed |
| US-20150031747-A1 | METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2812433-A1 | METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013119979-A1 | METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| EP-1005361-B1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY | NOVO NORDISK HEALTHCARE AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20070232542-A1 | Methods for Modifying Cell Motility Using Factor VIIa Antagonist | NOVO NORDISK A/S (DK) | 2007-10-04 | — | — | US | disclosed |
| US-20070232542-A1 | Methods for Modifying Cell Motility Using Factor VIIa Antagonist | NOVO NORDISK A/S (DK) | 2007-10-04 | — | — | US | disclosed |
| US-20050245449-A1 | Methods for modifying cell motility using factor VIIa antagonist | NOVO NORDISK, A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| US-20030040481-A1 | Methods for modifying cell motility using a factor VIIa antagonist | NOVO NORDISK HEALTHCARE A/G (CH) | 2003-02-27 | — | — | US | disclosed |
| US-6461610-B1 | Methods for modifying cell motility using factor VIIa or inactivated factor VIIa | NOVO NORDISK A/S (DK) | 2002-10-08 | — | — | US | disclosed |
| US-6268163-B1 | DETECTION OF MODULATORS OF MEMBRANE PROTEIN ACTIVITY; CULTURE CELLS, MEASURE ACTIVATION OF MITOGEN ACTIVATED PROTEIN KINASE, COMPARE WITH CONTROL, ADJUSTMENT IN ACTIVATION INDICATES MODULATION OF SIGNAL TRANSDUCTION | NOVO NORDISK A/S (DK) | 2001-07-31 | — | — | US | disclosed |
| EP-1005361-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999003498-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 1999-01-28 | — | — | WO | disclosed |
| US-5859010-A | ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 1999-01-12 | — | — | US | disclosed |
| WO-1997049684-A1 | FACTOR VII-BINDING REAGENT | NOVO NORDISK A/S (DK) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245449-A1 | Methods for modifying cell motility using factor VIIa antagonist | TFPI, TFPI2, F13B | HDAC6 1886/4885POLB 3200/4885KDM4E 3750/4885 |
| US-20030040481-A1 | Methods for modifying cell motility using a factor VIIa antagonist | TFPI, TFPI2, F13B | HDAC6 1610/4885POLB 3642/4885KDM4E 3599/4885 |
| US-20070232542-A1 | Methods for Modifying Cell Motility Using Factor VIIa Antagonist | TFPI, TFPI2, F13B | HDAC6 1886/4885POLB 3200/4885KDM4E 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.